Dermira Inc (DERM) was Reiterated by Needham to “Buy” according to the research note released today. The brokerage firm has raised the Price Target to $ 46 from a previous price target of $42 . Needham advised their investors in a research report released on Jun 2, 2016.
Many Wall Street Analysts have commented on Dermira Inc. Company shares were Reiterated by Wedbush on Jun 2, 2016 to “Outperform”, Firm has raised the Price Target to $ 46 from a previous price target of $42 .Company shares were Reiterated by Needham on May 11, 2016 to “Buy”, Firm has raised the Price Target to $ 42 from a previous price target of $38 .
Dermira Inc opened for trading at $31.36 and hit $32.36 on the upside on Wednesday, eventually ending the session at $32, with a gain of 0.82% or 0.26 points. The heightened volatility saw the trading volume jump to 3,30,551 shares. Company has a market cap of $961 M.
In a different news, on May 3, 2016, Eugene A Bauer (Chief Medical Officer) sold 2,500 shares at $25.09 per share price. According to the SEC, on May 3, 2016, Thomas G Wiggans (CEO & Chairman of the Board) sold 9,000 shares at $25.11 per share price.
Dermira Inc. is a specialty biopharmaceutical company focused on bringing medical dermatology products to dermatologists and their patients. The Company’s portfolio of five product candidates includes three late-stage product candidates. The late-stage product candidates are Cimzia (certolizumab pegol) which the Company is developing in collaboration with UCB Pharma S.A. (UCB) DRM04 and DRM01. Cimzia is an injectable biologic tumor necrosis factor-alpha inhibitor or TNF inhibitor that is approved and marketed by UCB for the treatment of numerous inflammatory diseases spanning multiple medical specialties. DRM04 is a topical small-molecule anticholinergic product the Company is developing for the treatment of hyperhidrosis or excessive sweating. DRM01 is a topical small-molecule sebum inhibitor the Company is developing for the treatment of acne.